Page 66 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation
P. 66
Chapter 3
Acknowledgements
This work was financially supported by an Alpe d’Huzes/KWF fund provided by the Dutch Cancer Society (# VU 2012-5848). The authors would like to thank the authors of the primary studies that replied to the requests and kindly provided additional information or analyses.
Funding
This work was financially supported by an Alpe d’Huzes/KWF fund provided by the Dutch Cancer Society (# VU 2012–5848).
64
